Transgene: Focus on 2013 with key milestones expected
CORPORATE, Fair Value EUR21 (+147%)
Transgene released its full year results with a EUR43.2m loss driven by R&D expenses (EUR48.7m) linked by TG4010 and JX594 clinical trials. The cash position is EUR92.9m at year end while Transgene expects cash consumption of EUR50m in 2013. 2013 will definitely be an important year for Transgene given the eagerly awaited clinical results of TG4010 and JX594.
Full report available to subscribers
Please contact firstname.lastname@example.org